Patents by Inventor Jung-Min Kee
Jung-Min Kee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220220134Abstract: Provided are phosphonopyrazole-based phosphohistidine analogs that are useful as haptens for the preparation of immunogens, immunogens that include these haptens linked to carrier molecules, antibodies thereto and uses of these antibodies, haptens, immunogens and phosphohistidine analogs.Type: ApplicationFiled: March 29, 2022Publication date: July 14, 2022Applicant: The Trustees of Princeton UniversityInventors: Tom W. Muir, Rob C. Oslund, Jung-Min Kee
-
Patent number: 10351581Abstract: Provided are phosphonopyrazole-based phosphohistidine analogs that are useful as haptens for the preparation of immunogens, immunogens that include these haptens linked to carrier molecules, antibodies thereto and uses of these antibodies, haptens, immunogens and phosphohistidine analogs. The invention is based in part on new pHis analogs that are chemically stable and which have been used as haptens and immunogens to generate specific anti-pHis antibodies that bind with high affinity and specificity.Type: GrantFiled: October 2, 2014Date of Patent: July 16, 2019Assignee: THE TRUSTEES OF PRINCETON UNIVERSITYInventors: Tom W. Muir, Rob C. Oslund, Jung-Min Kee
-
Publication number: 20190092796Abstract: Provided are phosphonopyrazole-based phosphohistidine analogs that are useful as haptens for the preparation of immunogens, immunogens that include these haptens linked to carrier molecules, antibodies thereto and uses of these antibodies, haptens, immunogens and phosphohistidine analogs.Type: ApplicationFiled: September 19, 2018Publication date: March 28, 2019Applicant: The Trustees of Princeton UniversityInventors: Tom W. Muir, Rob C. Oslund, Jung-Min Kee
-
Patent number: 9765154Abstract: The present invention relates to the phosphohistidine analogs of the present invention which of the formula and the hapten containing the residue of same. It also relates to the hapten conjugated to a carrier molecule and the isolated antibodies raised against the immunogens, said antibodies recognizing polypeptide containing a phosphorylated histidine or the phosphotriazole residue but it does not recognize an amino acid or polypeptide that is not phosphorylated or a polypeptide which is phosphorylated on amino acids other than histidine but not on histidine.Type: GrantFiled: May 11, 2015Date of Patent: September 19, 2017Assignee: THE ROCKEFELLER UNIVERSITYInventors: Tom W. Muir, Jung-Min Kee
-
Publication number: 20160311838Abstract: Provided are phosphonopyrazole-based phosphohistidine analogs that are useful as haptens for the preparation of immunogens, immunogens that include these haptens linked to carrier molecules, antibodies thereto and uses of these antibodies, haptens, immunogens and phosphohistidine analogs. The invention is based in part on new pHis analogs that are chemically stable and which have been used as haptens and immunogens to generate specific anti-pHis antibodies that bind with high affinity and specificity.Type: ApplicationFiled: October 2, 2014Publication date: October 27, 2016Inventors: Tom W. Muir, Rob C. Oslund, Jung-Min Kee
-
Publication number: 20150344589Abstract: The present invention relates to the phosphohistidine analogs of the present invention which of the formula and the hapten containing the residue of same. It also relates to the hapten conjugated to a carrier molecule and the isolated antibodies raised against the immunogens, said antibodies recognizing polypeptide containing a phosphorylated histidine or the phosphotriazole residue but it does not recognize an amino acid or polypeptide that is not phosphorylated or a polypeptide which is phosphorylated on amino acids other than histidine but not on histidine.Type: ApplicationFiled: May 11, 2015Publication date: December 3, 2015Applicant: THE ROCKEFELLER UNIVERSITYInventors: Tom W. MUIR, Jung-Min KEE
-
Patent number: 9035068Abstract: The present invention relates to the phosphohistidine analogs of the present invention which of the formula (I) and the hapten containing the residue of same. It also relates to the hapten conjugated to a carrier molecule and the isolated antibodies raised against the immunogens, said antibodies recognizing polypeptide containing a phosphorylated histidine or the phosphotriazole residue but it does not recognize an amino acid or polypeptide that is not phosphorylated or a polypeptide which is phosphorylated on amino acids other than histidine but not on histidine.Type: GrantFiled: September 23, 2011Date of Patent: May 19, 2015Assignee: THE ROCKEFELLER UNIVERSITYInventors: Tom W. Muir, Jung-Min Kee
-
Publication number: 20130260398Abstract: The present invention relates to the phosphohistidine analogs of the present invention which of the formula (I) and the hapten containing the residue of same. It also relates to the hapten conjugated to a carrier molecule and the isolated antibodies raised against the immunogens, said antibodies recognizing polypeptide containing a phosphorylated histidine or the phosphotriazole residue but it does not recognize an amino acid or polypeptide that is not phosphorylated or a polypeptide which is phosphorylated on amino acids other than histidine but not on histidine.Type: ApplicationFiled: September 23, 2011Publication date: October 3, 2013Applicant: THE ROCKEFELLER UNIVERSITYInventors: Tom W. Muir, Jung-Min Kee
-
Patent number: 8536378Abstract: This invention concerns product and process to convert a hydroxyl group (bold in R3C—OH) in a tigliane-type compound to a hydrogen (bold in R3C—H) to obtain deoxytigliane-type compounds or structural or functional analogs thereof. The process has wide application particularly to produce specific biologically active compounds in quantity for use as pharmaceuticals. In particular the process can be used to convert phorbol to a 12-deoxytigliane (prostratin), which is a therapeutic lead for the treatment of AIDS. New compositions of matter are also disclosed.Type: GrantFiled: November 1, 2011Date of Patent: September 17, 2013Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Paul A. Wender, Jeffrey M . Warrington, Jung-Min Kee
-
Publication number: 20120101283Abstract: This invention concerns product and process to convert a hydroxyl group (bold in R3C—OH) in a tigliane-type compound to a hydrogen (bold in R3C—H) to obtain deoxytigliane-type compounds or structural or functional analogs thereof. The process has wide application particularly to produce specific biologically active compounds in quantity for use as pharmaceuticals. In particular the process can be used to convert phorbol to a 12-deoxytigliane (prostratin), which is a therapeutic lead for the treatment of AIDS. New compositions of matter are also disclosed.Type: ApplicationFiled: November 1, 2011Publication date: April 26, 2012Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Paul A. Wender, Jeffrey Warrington, Jung-Min Kee
-
Patent number: 8067632Abstract: This invention concerns a process to convert a hydroxyl group (bold in R3C—OH) in a tigliane-type compound to a hydrogen (bold in R3C—H) to obtain deoxytigliane-type compounds or structural or functional analogs thereof. The process has wide application particularly to produce specific biologically active compounds in quantity for use as pharmaceuticals. In particular the process can be used to convert phorbol to a 12-deoxytigliane (prostrating which is a therapeutic lead for the treatment of AIDS. New compositions of matter are also disclosed.Type: GrantFiled: July 24, 2008Date of Patent: November 29, 2011Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Paul A. Wender, Jeffrey Warrington, Jung-Min Kee
-
Publication number: 20090187046Abstract: This invention concerns a process to convert a hydroxyl group (bold in R3C—OH) in a tigliane-type compound to a hydrogen (bold in R3C—H) to obtain deoxytigliane-type compounds or structural or functional analogs thereof. The process has wide application particularly to produce specific biologically active compounds in quantity for use as pharmaceuticals. In particular the process can be used to convert phorbol to a 12-deoxytigliane (prostrating which is a therapeutic lead for the treatment of AIDS. New compositions of matter are also disclosed.Type: ApplicationFiled: July 24, 2008Publication date: July 23, 2009Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Paul A. Wender, Jeffrey Warrington, Jung-Min Kee